Abstracts & Manuscripts

Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)

Pennipede D, Mohyuddin GR, Hawkins R, Ganguly S, Shune L, Ahmed N, Mohan M, Cui W, Mahmoudjafari Z, McGuirk J, Atrash S, Abdallah AO. Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM). Eur J Haematol. 2021 Dec;107(6):602-608. doi: 10.1111/ejh.13697. Epub 2021 Aug 31. PMID: 34378251.

Car-T Treatment for Hematological Malignancies - Shebli Atrash, Kulsum Bano, Bradley Harrison, Al-Ola Abdallah, 2020 (sagepub.com)

Atrash S, Bano K, Harrison B, Abdallah AO. CAR-T treatment for hematological malignancies. J Investig Med. 2020 Jun;68(5):956-964. doi: 10.1136/jim-2020-001290. Epub 2020 Mar 21. PMID: 32200355.

Dawn of Hope for Improved Access to BCMA Therapy: Chimeric Antigen Receptor T Cell and Bispecific Products - ScienceDirect

Ahmed N, Wesson W, Abdallah AO. Dawn of Hope for Improved Access to BCMA Therapy: Chimeric Antigen Receptor T Cell and Bispecific Products. Transplant Cell Ther. 2023 Apr 22:S2666-6367(23)01244-7. doi: 10.1016/j.jtct.2023.04.013. Epub ahead of print. PMID: 37094702

Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma - ScienceDirect

Atieh T, Atrash S, Ahmed N, Mohan M, Cui W, Shune L, Hajjar S, Mahmoudjafari Z, Quick J, Wishna A, Riffel J, McGuirk J, Mohyuddin GR, Abdallah AO. Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 Dec;22(12):912-919. doi: 10.1016/j.clml.2022.08.003. Epub 2022 Aug 15. PMID: 36127271.

Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma - Abdallah - 2023 - European Journal of Haematology - Wiley Online Library

Abdallah AO, Mahmoudjafari Z, Ahmed N, Cui W, Shune L, McGuirk J, Mohan M, Mohyuddin GR, Afrough A, Alkharabsheh O, Atrash S. Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma. Eur J Haematol. 2023 Jun;110(6):626-632. doi: 10.1111/ejh.13942. Epub 2023 Feb 21. PMID: 36752328.

Neutralizing antibody responses against SARS‐CoV‐2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination - Abdallah - 2022 - European Journal of Haematology - Wiley Online Library

Abdallah AO, Mahmoudjafari Z, Atieh T, Ahmed N, Cui W, Shune L, Mohan M, McGuirk J, Remker C, Foss M, Karloff E, Fitch H, Atrash S. Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination. Eur J Haematol. 2022 Nov;109(5):458-464. doi: 10.1111/ejh.13826. Epub 2022 Jul 26. PMID: 35810359; PMCID: PMC9350358.

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease - PMC (nih.gov)

Abdallah AO, Mohyuddin GR, Ahmed N, Mohan M, Cui W, Shune L, Mahmoudjafari Z, McGuirk J, Ganguly S, Atrash S. Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease. EJHaem. 2021 Sep 16;2(4):757-764. doi: 10.1002/jha2.275. PMID: 35845187; PMCID: PMC9175829.

Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma - ScienceDirect

Abdallah AO, Mohyuddin GR, Mahmoudjafari Z, Atrash S, Kawsar H, Sigle M, Shune L, McGuirk J, Ganguly S. Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):e212-e219. doi: 10.1016/j.clml.2020.08.026. Epub 2020 Sep 18. PMID: 33051166.

Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone - PMC (nih.gov)

Alkharabsheh O, Bellman P, Mahmoudjafari Z, Cui W, Atrash S, Paul B, Hashmi H, Shune L, Ahmed N, Abdallah AO. Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone. J Hematol. 2023 Feb;12(1):1-6. doi: 10.14740/jh1085. Epub 2023 Feb 25. PMID: 36895290; PMCID: PMC9990715.

Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma - ScienceDirect

Hashmi H, Atrash S, Jain J, Khasawneh G, Mohan M, Mahmoudjafari Z, Cui W, McGuirk J, Shune L, Ahmed N, Abdallah AO. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma. Transplant Cell Ther. 2023 Apr;29(4):262.e1-262.e6. doi: 10.1016/j.jtct.2023.01.013. Epub 2023 Jan 20. PMID: 36682468.